| |
| | CDER Antimicrobial Resistance |
 | | FDA, in cooperation with other Public Health Service Agencies, has embarked on several major initiatives to address what is considered to be a major threat to the Public Health in the new millennium: the emergence of drug-resistant bacteria. |
 | | This page is designed to permit ready access to FDA and CDER activities, initiatives, policies, and information regarding antimicrobial resistance (also known as drug resistance or antibiotic resistance), both for health professionals and consumers. |
 | | CDER, the Center for Drug Evaluation and Research, is home to (among others) the Divisions of Anti-Infective Drug Products, Special Pathogen and Immunologic Drug Products, Antiviral Drug Products (all within the Office of Drug Evaluation IV), the Division of Over-the-Counter Drug Products (within the Office of Drug Evaluation V), and the Office of Generic Drugs. |
| www.fda.gov /cder/drug/antimicrobial (427 words) |
|